P536: Minimally invasive gasless technique for ileocolic resection using an existing McBurney incisionECCO '18 Vienna
2018
P537: Adalimumab: Relevance of drug trough levels and antibodies assessment in the prognosis of Crohn’s diseaseECCO '18 Vienna
2018
P538: Enteral nutrition for the maintenance of remission in adults with inactive Crohn’s disease: A meta-analysisECCO '18 Vienna
2018
P539: Transcriptional changes in mucosal inflammation associated with an autoimmune protocol diet for ulcerative colitisECCO '18 Vienna
2018
P540: Early response as a prognostic factor for vedolizumab: A real-life experience from a single Italian tertiary centreECCO '18 Vienna
2018
P541: Clinical factors associated with discontinuation of combo or monotherapy for Crohn’s disease: A sub-analysis of a prospective randomised clinical trial (DIAMOND study)ECCO '18 Vienna
2018
P542: Infliximab salvage therapy in acute severe ulcerative colitis: A systematic review and meta-analysisECCO '18 Vienna
2018
P543: Higher post-induction infliximab serum trough levels are associated with healing of fistulising perianal Crohn’s disease in childrenECCO '18 Vienna
2018
P544: Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE studyECCO '18 Vienna
2018
P545: Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognitionECCO '18 Vienna
2018
P546: Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim resultsECCO '18 Vienna
2018
P548: Limited clinical value in assessing the distribution of endoscopic disease activity in patients with ulcerative colitisECCO '18 Vienna
2018
P549: Systemic cytomegalovirus infection is a relevant factor affecting short- and long-term outcomes of patients with acute severe ulcerative colitis: An 11-year experienceECCO '18 Vienna
2018
P550: Early 12-week ultrasound response to treatment, used as a predictor of response at 6 months in Crohn’s disease: A prospective cohort studyECCO '18 Vienna
2018
P551: 6-Thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn’s disease: A multi-centre, international studyECCO '18 Vienna
2018
P552: Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisationECCO '18 Vienna
2018
P553: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumabECCO '18 Vienna
2018